STAGEOSIS
LIVE

Serial Number

79408532

Owner

GENFIT

Attorney

Ronald M. Kachmarik

Filing Date

Sep 19, 2024

Add to watchlist:

No watchlists yet
View on USPTO

STAGEOSIS Trademark

Serial Number: 79408532 • Registration: 7877216

STAGEOSIS is a trademark filed by GENFIT on September 19, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

GENFIT (44 trademarks)

885 rue Eugene Avinee
Loos 59120 , FR

Entity Type: 03

Trademark Details

Filing Date

September 19, 2024

Registration Date

August 5, 2025

Published for Opposition

June 17, 2025

Goods & Services

Scientific and technological services, namely research in the medical, biomedical, and chemical fields, for the diagnosis, prevention and treatment of metabolic, hepatic and oncological diseases and disorders; biological research; clinical research and medical research in the field of diagnosis, prevention and treatment of metabolic, hepatic and oncological diseases and disorders; industrial analysis and industrial research services in the field of pharmacy; design and development of computer hardware and software; programming for computers

Diagnostic preparations for industrial and scientific use; chemical reagents for industrial use; chemical reagents for scientific use

Medical apparatus, instruments and equipment namely, DNA, RNA and protein analysis apparatus, DNA, RNA and protein quantifiers, medical devices for measuring DNA, RNA, biochemical and physical parameters, namely, concentration of biomarkers and blood analyzers for evaluation of metabolic, hepatic and oncological diseases and disorders; instruments and tools for medical diagnosis, namely diagnostic medical devices for diagnosis of metabolic, hepatic and oncological diseases and disorders, blood analysis apparatus, DNA and RNA analysis apparatus, gene analyzers, medical devices for measuring biochemical and physical parameters, namely, concentration of biomarkers relating to the evaluation of metabolic, hepatic and oncological diseases and disorders, and blood analyzers for evaluation of metabolic, hepatic and oncological diseases and disorders

Medical analysis for the diagnosis, prevention and treatment of metabolic, hepatic and oncological diseases and disorders; medical analysis of blood samples; assistance services in the fields of medicine and health care; medical information; provision of medical information

Pharmaceutical preparations for the diagnosis, prevention and treatment of metabolic, hepatic and oncological diseases and disorders; diagnostic preparations and diagnostic biomarker reagents for medical use; medical diagnostic testing materials for medical use namely, diagnostic reagents and assays for testing of bodily fluids; blood and blood-derived samples for medical use, namely, blood substitutes for human use, blood plasma, serum and other blood-derived biological samples

Downloadable and recorded software for use in the management of cancer, metabolic diseases and liver diseases, namely, software for creating customized care plans for patients, for managing patient data, for providing clinical decision support information and analytics, for managing patient medications, and for providing reporting and analytics relating to patient care, and for use in research and development of new pharmaceutical products for others, namely, software for managing, analyzing and reporting on clinical trial data; downloadable software applications for use in diagnosing medical conditions; scientific apparatus and instruments for recording, processing, reproduction and transmission of data, namely electronic data loggers and recorders; data processing equipment

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 16, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 30, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 29, 2026 OPNR
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 5, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 15, 2026 FICS
FINAL DISPOSITION PROCESSED
Feb 15, 2026 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 5, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 5, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 5, 2025 R.PR
NEW REPRESENTATIVE AT IB RECEIVED
Jun 19, 2025 NREP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 17, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 17, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 11, 2025 NONP
REFUSAL PROCESSED BY IB
May 31, 2025 RFNT
APPROVED FOR PUB - PRINCIPAL REGISTER
May 19, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 16, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 16, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 16, 2025 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 10, 2025 RFCS
REFUSAL PROCESSED BY MPU
May 10, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 22, 2025 RFCR
NON-FINAL ACTION WRITTEN
Mar 21, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 17, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 5, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 5, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 31, 2024 REPR